Your antigen and our skilled technical staff create an ideal combination for your custom antibody requirements. We keep your project in strict confidence. Any hybridoma cell lines that we develop for you remain your exclusive property.

The successful development of hybridoma cell lines producing monoclonal antibodies depends on three factors: 1) the immune system of the host 2) the antigen and 3) the assay used to measure antigen-antibody binding.

The project length depends on these factors. Large, highly immunogenic antigens typically result in many hybridoma cell lines from a limited number of immunized mice. Small, highly conserved antigens often require more immunizations, mice, and screening to select an appropriate antibody-producing cell line.

Our hybridoma development process

The four stages of our hybridoma development define critical project milestones. Because we invoice when milestones are reached, you pay only for work completed.

Stage I (Weeks 1-7): Establish project web site. Immunize mice. Screen sera by ELISA for immune response.

Mice receive an initial injection on Day 0 in Complete Freund's adjuvant, and booster injections in Incomplete Freund's on Days 14 and 28. Serum is collected and the titer is determined. Samples are available for testing in your assays at your facility. Booster injections are given until one or more mice have appropriate titers.